Aveo Pharmaceuticals Inc (AVEO) 10K Annual Reports & 10Q SEC Filings

– Long-term data from pivotal TIVO-3 study presented at ASCO GU 2022 continue to demonstrate durable disease control and positive trend for overall survival for FOTIVDA –

– Company to Host Conference Call Today at 8:30 a.m. ET –

BOSTON – March 14, 2022 – AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided financial guidance for 2022.

“We have seen quarter over quarter growth in FOTIVDA® (tivozanib) sales since its commercial launch on March 22, 2021, including closing the year with U.S. net product revenue of $38.9 million for 2021 and $16.8 million of U.S. net product revenue in the fourth quarter of 2021. As we look to 2022, we expect to build on our commercial momentum by continuing to expand our prescriber base and increase the utilization of FOTIVDA in the third-line setting. We believe we made significant progress on both fronts in 2021 and look to build on this momentum in 2022,” said Michael Bailey, President and Chief Executive Officer of AVEO. “In addition to our commercial team's educational and awareness initiatives, we believe the long-term progression free survival (PFS) data presented last month at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) further support the durability of disease control demonstrated by FOTIVDA in the third- and fourth-line treatment setting. This marks the first presentation of five year follow-up data for patients being treated in this setting and helps guide clinical treatment. As we look ahead to 2022 and beyond, we remain confident that FOTIVDA has the potential to become a standard of care for adult patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) that have received two or more prior systemic treatments.”

“Our clinical team continues to make steady progress with expanding the opportunities for FOTIVDA in an effort to move to earlier settings in combinations with novel therapies as well as advancing our pipeline of monoclonal antibodies that collectively we believe will build long-term value for our shareholders.”

Fourth Quarter 2021 and Recent Highlights

•Ended 2021 with quarter over quarter growth of FOTIVDA net sales and prescriptions heading into 2022

◦Fourth quarter 2021 U.S. net product revenue increased 17% from $14.3 million U.S. net product revenue in the third quarter of 2021 to $16.8 million, which reflects inventory shipped to distributors and a gross-to-net estimate of 14% during the fourth quarter. As of

The following information was filed by Aveo Pharmaceuticals Inc (AVEO) on Monday, March 14, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1325879/000162828022006093/aveo-20211231.htm

View differences made from one year to another to evaluate Aveo Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aveo Pharmaceuticals Inc.

Continue

Assess how Aveo Pharmaceuticals Inc's management team is paid from their Annual Proxy

Aveo Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Aveo Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits

Exhibit 3.1: Articles Of Incorporation

Exhibit 10.19: Material Contract

Exhibit 10.20: Material Contract

Exhibit 10.21: Material Contract

Exhibit 10.22: Material Contract

Exhibit 10.23: Material Contract

Exhibit 10.24: Material Contract

Exhibit 10.32: Material Contract

Exhibit 10.39: Material Contract

Exhibit 10.47: Material Contract

Exhibit 10.48: Material Contract

Exhibit 21.1: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: AVEO
CIK: 1325879
Form Type: 10-K Annual Report
Accession Number: 0001628280-22-006093
Submitted to the SEC: Mon Mar 14 2022 5:04:39 PM EST
Accepted by the SEC: Mon Mar 14 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/aveo/0001628280-22-006093.htm

Aveo Pharmaceuticals, Inc. (AVEO) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

AVEO Valuations

AVEO Annual Reports

AVEO Quarterly Reports

AVEO Corporate News